Tianjin Biopharmaceutical Innovation Park To Start Operation In April
This article was originally published in PharmAsia News
China's biopharmaceutical international innovation park, sited in Tianjin Economic-Technological Development Area, has completed its phase one construction and will go into operation in April. To date, the park has received more than 170 domestic and overseas applications of R&D projects; it has already confirmed the location of four industrial companies with investment of over RMB100 million ($14.61 million) each. Tianjin International Biomedical Research Institute, the park's core component, will by year end establish a series of technical platforms including its clinical trial center, drug analysis and testing center, and information center. By the end of 2010, the park will be a world-class biopharmaceutical R&D base with more than 100 R&D teams and 1,000 people. (Click here for more - Chinese Language)
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.